Subscribe - Individual

Subscribe - Biotech Premium (Corporate)

Categories

CUV1
November 20th, 2023

Clinuvel Pharmaceuticals - Core Growth Focus Ahead

Clinuvel Pharmaceuticals (CUV: $16.62) has built a profitable business from the successful commercialization of Scenesse, a drug indicated for the treatment of EPP (erythropoietic protoporphyria). In the last financial year, revenue was up 19% and net profit was up 46% to $30.6 million. The company finished June with a cash balance of $157 million.

IMU1
November 20th, 2023

First Results for Imugene's Oncolytic Virus CF33

In May last year, Imugene (IMU: $0.089) commenced the first study with its novel oncolytic virus, CF33. CF33 was invented by Dr Yuman Fong and his team at City of Hope. It was in-licensed by Imugene in 2019 with the first clinical study having started in May last year.

CHM1
November 3rd, 2023

Chimeric Therapeutics - Four Phase Ib Studies in 2024 Ahead of Partnering Deals

For Chimeric Therapeutics (CHM: $0.029), achieving Phase Ib data from its programs is expected to position the company for licensing deals ahead of registration Phase II studies with CAR-T cell therapies.

AVR2
November 3rd, 2023

Anteris Technologies Secures $40 Million in Capital Raise to Prepare for Pivotal Study

Novel heart valve development company Anteris Technologies (AVR: $20.00) has secured commitments to raise $40 million at $20 per share through a private placement.

IMC_1
November 3rd, 2023

Immuron Achieves Record Travelan Sales in September Quarter

Immuron (IMC: $0.075) has reported a record $1.5 million in sales in the September quarter for its Travelan product used to prevent travelers' diarrhea.

ARX1
November 3rd, 2023

Aroa Biosurgery – On track for Revenue of NZ$72 - NZ$75 Million

Aroa Biosurgery (ARX: $0.79), a wound-healing products company, continues its resilient performance with a 35% increase in cash receipts during the September quarter compared to the PCP. Total revenue during the September quarter was NZ$14.8 million.

NEU1
November 3rd, 2023

Neuren Pharmaceuticals – Strong DAYBUE Sales in September Quarter at US$67 million

–3 November 2023–

Neuren  Pharmaceuticals' (NEU: $11.29) partner Acadia Pharmaceuticals has reported a strong second quarter of sales of its drug DAYBUE for Rett syndrome after having been launched in the US in April this year.

cogstate
October 10th, 2023

Acquisition Targets for Australian Biotech Sector (Cogstate)

Over the next 12-24 months a number of companies in the sector may receive acquisition bids. The last company to be acquired was ResApp Health for $180 million by Pfizer in 2022. Three companies viewed as potential targets by Bioshares are discussed below.

dmx1
October 10th, 2023

Major Validation Deal for Dimerix

Dimerix (DXB: $0.16) has signed a licensing deal for its lead compound, DMX-200, with Advanz Pharma. The deal gives Advanz rights to the use of DMX-200 for the treatment of FSGS (Focal Segmental Glomerulosclerosis) in Europe, the UK, Canada, Australia and New Zealand.

AVR1
October 3rd, 2023

Acquisition Targets for Australian Biotech Sector (Anteris Technologies)

Over the next 12-24 months a number of companies in the sector may receive acquisition bids. The last company to be acquired was ResApp Health for $180 million by Pfizer in 2022. Three companies viewed as potential targets by Bioshares are discussed below.

Pages